Zydus Pharmaceuticals (USA) Inc., located in Pennington, New Jersey, has come a long way since its first commercial launch in August 2005. The company currently offers more than 430 SKUs to the US market and is ranked the seventh largest unbranded generic corporation in the US based on dispensed prescriptions (IQVIA, NPA audit, MAT June 2019). Since Zydus first entered the US market, it has purchased two facilities in the US– Nesher Pharmaceuticals in St Louis, Missouri and Hercon Pharmaceuticals in York, PA. In 2017, Zydus also acquired Sentynl Therapeutics Inc., a specialty pharmaceutical company based in Solana Beach, CA. These acquisitions have helped Zydus grow from a generic company focused on solid oral generics to a company that offers more complex dosage forms such as oral suspensions, modified-release oral solids, transdermals, controlled substances, and injectables. 

In the first half of the year, the company launched 15 product families and received final approval on 24 abbreviated new drug applications (ANDAs). Some of Zydus’ key launches include ambrisentan tablets, bosentan tablets, phytonadione tablets, and rivastigmine patches, Zydus’ first transdermal launch. Zydus also entered the dermatology space in the US market this year, with 5 topical launches. To prepare for the upcoming flu season, Zydus’ Nesher facility has been busy manufacturing its oseltamivir phosphate capsules and oral suspension to ensure seamless supply. As Zydus enters the second half of the year, it plans to bring many more cost-saving generics to market to help improve patients’ lives.

Zydus Pharmaceuticals’ parent company, Zydus Cadila, is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of therapies. Zydus Cadila, headquartered in Ahmedabad, India, is India’s 4th largest pharmaceutical company. The company has business operations in more than 50 countries, including the US, France, Spain, Brazil, Mexico, and South Africa. Zydus’ innovation program is spearheaded by 1,300 researchers across 19 sites, working on differentiated medicines for the future. From NCEs to vaccines, biosimilars, and niche technologies, the group is exploring different ideas and innovating constantly. Driven by creativity and innovation, Zydus Cadila strives for excellence and to make a difference in the world of pharmaceuticals and healthcare.

Zydus has grown tremendously over the past 14 years, and the company is continuing to look for new ways to bring value to the US market. Zydus is aggressively pursuing franchises to further its footprint in the lives of patients. The company has launched several products out of its oncology facility and launched its first dermatologic product this year. With the strength and worldwide reputation of Zydus Cadila supporting the US division, Zydus is looking forward to continuing its growth in the US marketplace. As the company focuses its efforts on more challenging and rewarding opportunities, including several first-to-file and 505(b)(2) opportunities, it looks forward to great success in the coming years. To date, Zydus has filed 105 drug master files, received final USFDA approval on 241 ANDAs, received tentative FDA approval on 18 ANDAs, and has over 100 ANDAs pending approval. The company also has approximately 300 additional products in various stages of development. Look for some exciting announcements from Zydus over the next 12 months, as they are truly poised for the future.